Blue Shield of California 1st insurer to cover rapid whole genome sequencing for critically ill children

Blue Shield of California is the first health plan to pay for rapid whole genome sequencing for critically ill children so physicians can quickly identify and decode the root causes of rare genetic disorders.

Advertisement

The insurer announced the expanded coverage March 9. The technology, made by Rady Children’s Institute for Genomic Medicine in San Diego, helps provide precision treatment to critically ill children and babies in intensive care who have unexplained medical conditions.

Using a blood sample, researchers at Rady Children’s Institute pinpoint a preliminary diagnosis in less than three days for medically urgent cases. Any hospital can send the samples to Rady Children’s for testing.

“Our system is optimized to identify or rule out most genetic diseases in a single test, and provide the medical team at the bedside with child-specific, disease-specific information so they can make better, faster medical decisions,” Stephen Kingsmore, MD, president and CEO of Rady Children’s, said in a prepared statement.

More articles on payers:
5 things to know about Harmony, the UnitedHealth plan directing members to Optum physicians
Cigna to run Houston Methodist’s health plan under new agreement
Humana to make value-based payments to Ochsner providers treating social determinants

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, TRC Healthcare

Advertisement

Next Up in GLP-1s

Advertisement

Comments are closed.